Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financia... ($M $M Shareholders' equity...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> TECHNOLOGY

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

Date:4/25/2008

$M $M

Shareholders' equity:

Common stock of 5p par value; 750.0 million

shares authorized; and 559.4 million shares

issued and outstanding (2007: 750.0 million

shares authorized; and 556.8 million shares

issued and outstanding)

48.8 48.7

Exchangeable shares: nil shares issued and

outstanding (2007: 0.7 million) - 33.6

Treasury stock (313.9) (280.8)

Additional paid-in capital 2,557.8 2,509.9

Accumulated other comprehensive income 32.4 55.7

Accumulated deficit (1,011.5) (1,140.1)

Total shareholders' equity 1,313.6 1,227.0

Total liabilities and shareholders' equity 4,322.1 4,330.1

Unaudited US GAAP results for the three months to March 31, 2008

Consolidated Statements of Operations

3 months to March 31, 2008 2007

$M $M

Revenues:

Product sales 631.7 461.5

Royalties 65.1 59.5

Other revenues 5.4 7.2

Total revenues 702.2 528.2

Costs and expenses:

Cost of product sales(1) (2) 90.3 65.3

Research and development(2) 119.1 79.0

Selling, general and administrative 293.0 213.8

Depreciation and amortization(1) 44.4 28.9

Gain on sale of product rights
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
6. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes

Post Your Comments:

(Date:12/15/2009)... Epeius Biotechnologies Corporation, an emerging leader in the ... of the cutting-edge science behind its lead oncology ... world rediscovered the Cyclin G1 gene ... and disease progression, and thus a prime target ... National Cancer Institute investigating the role of microRNAs ...

(Date:12/15/2009)... -- Repligen Corporation (Nasdaq: RGEN ) today ... research funding to support the ongoing development of ... Dystrophy Association (MDA). This grant will support ... GMP manufacture of a drug candidate for human ... only provides important funding for Repligen,s research but ...

(Date:12/15/2009)... NEW YORK, Dec. 15 Reportlinker.com ... is available in its catalogue: ,, ... - Market Forecasts to 2015, Pipeline Analysis ... http://www.reportlinker.com/p0168104/The-Future-of-Orphan-Diseases-Therapeutics---Market-Forecasts-to-2015-Pipeline-Analysis-and-Reimbursement.html ,, Summary ... latest research "The Future of Orphan Diseases ...

(Date:12/15/2009)... CHARLOTTESVILLE, Va., Dec. 15 AstraZeneca ... University of Virginia (UVa) in Charlottesville, today ... strategic research collaboration to enhance development of ... (CAD) with a secondary focus on peripheral ... ) ,, The collaborative preclinical research ...

[0] Scientists Rediscover Gene Target for Cancer Therapy [0] Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program [0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease

... 2008, Caraco,Pharmaceutical Laboratories, Ltd. (NYSE Alternext US: CPD) received ... as a follow up to the,last FDA inspection of ... in May 2008. As previously disclosed, a Form,483 notice ... Company,had responded to all the observations made in the ...

... Therapeutics,Inc., (Nasdaq: NLTX ), announced today that Peter ... investor conferences:, -- Rodman & Renshaw 10th Annual ... room on Monday, November 10, 2008 at The Palace ... 5th Annual Healthcare Conference at 9:00 a.m.,ET on Wednesday, ...

... today announced its lead sponsorship of the ... competition, held annually by the Massachusetts Institute ... brought together 84 undergraduate teams representing more ... Asia, Europe, Latin America, and the U.S. ...

Other Biology Technology:Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter 2 Nile Therapeutics to Present at Two Upcoming Investor Conferences 2 The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems 2 The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems 3

Caraco Pharmaceutical Laboratories, Ltd. Receives FDA Warning Letter Nile Therapeutics to Present at Two Upcoming Investor Conferences The MathWorks Sponsors iGEM Competition for Synthetic Biology at MIT : MATLAB and SimBiology Help Accelerate Design of Synthetic Biological Systems

(Date:12/16/2009)... N.Y. and FOOTHILL RANCH, Calif., Dec. 17 ... and Fujitsu Frontech North America Inc. today ... palm vein biometric technology from Fujitsu with ... ,, (Photo: http://www.newscom.com/cgi-bin/prnh/20091217/NY27736 ) ,, ... new offering aims to help companies bypass ...

(Date:12/16/2009)... its student travel award to attend the Biophysical Society,s ... San Francisco, California, February 20-24, 2010. The recipients of ... with priority given to those who will present a ... travel grant and will be recognized at a reception ... the Student Travel Award are: , , Katherine Alfieri, Haverford ...

(Date:12/16/2009)... superstitions and rituals can help them get psyched up ... drugs (NSAIDs), which many athletes gobble down before and ... good. , "These agents are treatments for the symptoms ... Warden, whose research at Indiana University focuses on musculoskeletal ... to exercise or train at a certain level, but ...

Breaking Biology News(10 mins):Fujitsu and IBM Offer Biometric Security Solution That Replaces Passwords With the Scan of an Employee's Palm 2 Fujitsu and IBM Offer Biometric Security Solution That Replaces Passwords With the Scan of an Employee's Palm 3 Fujitsu and IBM Offer Biometric Security Solution That Replaces Passwords With the Scan of an Employee's Palm 4 Fujitsu and IBM Offer Biometric Security Solution That Replaces Passwords With the Scan of an Employee's Palm 5 Biophysical Society announces winners of 2010 Student Travel Awards 2 Biophysical Society announces winners of 2010 Student Travel Awards 3 Biophysical Society announces winners of 2010 Student Travel Awards 4 NSAIDs: Take 'em early and often when competing? Think again 2 Psychiatrist Says Political Correctness Is Costing Lives 61818 1 Psychiatrist Says Political Correctness Is Costing Lives 61818 2 Statement by the Scientific Advisory Board of the Patient Advocate Foundation National Patient Advocate Foundation on Changes to the USPSTF Mammograph 61814 1 Statement by the Scientific Advisory Board of the Patient Advocate Foundation National Patient Advocate Foundation on Changes to the USPSTF Mammograph 61814 2 Novavax Prices Public Offering of Common Stock 14933 1 Novavax Prices Public Offering of Common Stock 14933 2

[0] Fujitsu and IBM Offer Biometric Security Solution That Replaces Passwords With the Scan of an Employee's Palm [0] Biophysical Society announces winners of 2010 Student Travel Awards [0] NSAIDs: Take 'em early and often when competing? Think again

... 2007 - EMD Serono, Inc. announced today the ... automated device in the growth hormone therapeutic area. ... Saizen [somatropin (rDNA origin) for injection], the companys ... Gold Medal recipient of the Medical Design Excellence ...

... Attendees, Choice Awards, NEW YORK, Dec. 5 ... Caesars Palace, Las Vegas, Nov. 27 - 30,was the ... sellers held in the U.S. with over 1,600 attendees,representing ... countries., Attendees from AIG, Chevron, FedEx, GE, GM, ...

... the past 60 years, the National Academies have studied ... of the atomic bombs dropped on Hiroshima and Nagasaki, ... Commission (ABCC), the study group was reorganized in 1975 ... is now a cooperative Japan-U.S. research organization. To ...

Other Biology News:EMD Serono launches easypod, new electronic growth hormone injection device 2 EMD Serono launches easypod, new electronic growth hormone injection device 3 Record Attendance at the 2007 National Ergonomics Conference and Exposition 2 Atomic bomb survivor, scientists mark 60 years of long-term radiation study 2

EMD Serono launches easypod, new electronic growth hormone injection device Record Attendance at the 2007 National Ergonomics Conference and Exposition Atomic bomb survivor, scientists mark 60 years of long-term radiation study

... a comprehensive epitope analysis service utilizing ... Paraflo microfluidic chips for immunological studies, ... comprehensive service includes assistance with your ... provided by you, single or dual ...

... LX80L is an extension of Parkers MX80 family ... compact cross-section. LX80L bolt hole patterns mimic the ... units and all accessory brackets to build multi-axis ... travel to 750 mm , Accelerations to 5 ...

... the next step in the evolution of ... system that delivers labware to multiple laboratory ... times the throughput of ordinary microplate robots. ... variety of configurations to meet any labs ...

... The HybArray 12™ is an automated hybridization ... The system automates both the hybridization and ... glass slides. A single instrument can process ... in pairs and has multi-protocol software, enabling ...

Biology Products:

Epitope Peptide Microarray - Comprehensive Service from LC Sciences LX80 Series Precision Stages from Parker Hannifin Corporation LabLinx from Hudson Control Group, Inc.HybArray 12 DNA hybridization system from PerkinElmer

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financia...($M $M Shareholders' equity...)